The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has proposed the continuation and expansion of the Drug-Induced Liver Injury Network (DILIN). As described in the RFA, DILIN will evolve into a network of up to 8 Clinical Centers (CCs), the Data Coordinating Center (DCC), and the NIDDK Project Office. The purpose of this research program is to enhance the enrollment of cases and controls from a wide demographic and geographic distribution, devise testable hypotheses to assess the role of genetic variability in DILI, perform pharmacogenetic analysis and develop the infrastructure needed to find phenotypic-genotypic associations, disseminate the information to the greater scientific community, and develop, in conjunction with the National Library of Medicine, an authoritative and complete internet website for drug-induced liver injury. The Duke Clinical Research Institute (DCRI) proposes to continue as the DCC for DILIN. In this role, we will apply our extensive experience and research infrastructure to coordinate, support and facilitate the activities of the network. In particular, we will attend to the following specific aims: (1) nurture the efficient organizational structure developed in the initial grant period;(2) invoke quality assurance procedures to ensure fidelity in conducting these studies;(3) integrate the new clinical centers into DILIN;(4) maintain data management systems developed in the initial grant period to safeguard the completeness, accuracy and timeliness of the accumulating data;(5) continue reports developed in the initial grant period to chart progress in conducting these studies;(6) contribute in a substantive manner to design and conduct of pharmacogenetic studies;(7) contribute to the NLM initiative to developed an authoritative DILI website;(8) contribute to the development of a validated, diagnostic instrument for DILI;(9) provide appropriate and capable leadership and expertise in biostatistics and study design;and (10) support ancillary studies and prospective studies.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (O1))
Program Officer
Serrano, Jose
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Biostatistics & Other Math Sci
Schools of Medicine
United States
Zip Code
Kleiner, David E; Chalasani, Naga P; Lee, William M et al. (2014) Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 59:661-70
Fontana, Robert J; Hayashi, Paul H; Gu, Jiezhun et al. (2014) Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 147:96-108.e4
Russo, Mark W; Hoofnagle, Jay H; Gu, Jiezhun et al. (2014) Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology 60:679-86
deLemos, Andrew S; Foureau, David M; Jacobs, Carl et al. (2014) Drug-induced liver injury with autoimmune features. Semin Liver Dis 34:194-204
Ghabril, Marwan; Fontana, Robert; Rockey, Don et al. (2013) Drug-induced liver injury caused by intravenously administered medications: the Drug-induced Liver Injury Network experience. J Clin Gastroenterol 47:553-8
Ghabril, Marwan; Bonkovsky, Herbert L; Kum, Clarissa et al. (2013) Liver injury from tumor necrosis factor-* antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 11:558-564.e3
Larion, Sebastian; Caballes, Frederick R; Hwang, Sun-Il et al. (2013) Circadian rhythms in acute intermittent porphyria--a pilot study. Eur J Clin Invest 43:727-39
Grant, Lafaine M; Kleiner, David E; Conjeevaram, Hari S et al. (2013) Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide. Dig Dis Sci 58:1415-21
Ryan Caballes, F; Sendi, Hossein; Bonkovsky, Herbert L (2012) Hepatitis C, porphyria cutanea tarda and liver iron: an update. Liver Int 32:880-93
Bell, L N; Vuppalanchi, R; Watkins, P B et al. (2012) Serum proteomic profiling in patients with drug-induced liver injury. Aliment Pharmacol Ther 35:600-12

Showing the most recent 10 out of 21 publications